Treatment of Metastatic Colon Cancer
Which systemic therapy is your typical first-line choice for a patient without prior chemotherapy with metastatic colon cancer in otherwise average health if the patient is the following age?
Which systemic therapy is your typical first-line choice for a patient without prior chemotherapy with metastatic colon cancer in otherwise average health if the patient is the following age?
How would you generally compare FOLFOX to FOLFIRI in the metastatic setting?
How would you generally compare FOLFOX to FOLFIRI in the metastatic setting?
For a 60-year-old patient without prior chemotherapy presenting with inoperable metastatic colon cancer and
PS2
due to cancer-related symptoms, who wants aggressive treatment, which
first-line
approach would you most likely recommend?
Case 3: Patient-related factors in the treatment of metastatic disease
Case 3: Patient-related factors in the treatment of metastatic disease
Case 3: Patient-related factors in the treatment of metastatic disease
Case 3: Patient-related factors in the treatment of metastatic disease
For how many patients with colon cancer have you used bevacizumab in the metastatic setting?
With informed patient consent, it is reasonable to use bevacizumab for patients with the following characteristics.
With informed patient consent, it is reasonable to use bevacizumab for patients with the following characteristics.
In the metastatic setting, at approximately what level for the following do you initiate antihypertensive therapy for patients on bevacizumab?
In the metastatic setting, at approximately what level for the following do you initiate antihypertensive therapy for patients on bevacizumab?
How would you compare FOLFOX with bevacizumab to FOLFIRI with cetuximab in the first-line metastatic setting?
How would you compare FOLFOX with bevacizumab to FOLFIRI with cetuximab in the first-line metastatic setting?
How many patients with colon cancer have you sent for surgical removal of hepatic metastases over the last three years?
For patients with colon cancer and liver metastases that are surgically removed, which postoperative treatment option would you most likely recommend for the patients who have had no prior chemotherapy?
Have you used the OncoSurge
®
decision tool in managing potentially surgically resectable hepatic metastases?
Case 4: Treatment algorithm for patients with isolated hepatic metastases
Case 5: Treatment of synchronous and primary metastatic disease
Case 5: Treatment of synchronous and primary metastatic disease
Case 6: Treating disease recurrence following adjuvant FOLFOX
Case 7: Continuation of bevacizumab beyond first-line disease progression
Case 8: Enrolling patients in clinical trials
Case 8: Enrolling patients in clinical trials
The results of the BRiTE registry, presented at ASCO 2007, have increased the likelihood that I may continue bevacizumab beyond metastatic disease progression.
Chemotherapy-free intervals are a reasonable option when administering FOLFOX for metastatic colon cancer.
Assume your patient is receiving FOLFOX or FOLFIRI, with bevacizumab. When utilizing “planned drug holidays” to minimize toxicity in the management of metastatic disease, do you routinely...?
Case 9: Second-line therapy for patients with metastatic disease
Case 9: Second-line therapy for patients with metastatic disease
For how many patients with colorectal cancer have you used cetuximab in the metastatic setting over the last year?
Would you consider using cetuximab for a patient whose tumor tested negative for EGFR?
The combination of cetuximab and bevacizumab (with or without chemotherapy) is a reasonable treatment approach off protocol in metastatic colon cancer.
